Alpha Tau Medical Ltd DRTS

JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in September 2026. Event:Citi's 2026 Biopharma Back to School ConferenceFormat:1x1 MeetingsDate:Wednesday, September 9, 2026Location:New York, NY Event:H.C. Wainwright 28th Annual Global Investor ConferenceFor

- IMPACT, a multicenter pilot study of Alpha DaRT® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total of 48 treated patients, driven by overwhelming demand from patients and clinicians - - Alpha DaRT is delivered as a one-time add-on alongside standard first-line chemotherapy, an approach supported by the favorable safety profile observed in the earlier Israeli and Canadian studie

By M. Marin NASDAQ: ORMP READ THE FULL ORMP RESEARCH REPORT Gains on investment portfolio + service agreement income contributed to 2Q26 EPS of $2.76 Oramed Pharmaceuticals (NASDAQ: ORMP) leverages its strong balance sheet, with $15.2 million of cash and equivalents and $50.6 million of cash and equivalents plus short-term investments, to allocate capital to investments in the biomedical and

WALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano,” or the “Company”) today announced the appointment of Nadav Kidron to its Board of Directors (the “Board”). As part of the Board’s ongoing strategic review, led by Chairman Phillip Borenstein, the Board intends to establish a Strategy and Capital Allocation Committee to support the Board’s evaluation of capital allocation alternatives, potential returns of excess capital to shareholders